Lumateperone - Intra-Cellular Therapies
Alternative Names: CAPLYTA; ITI-007; ITI-722; Lumateperone tosylateLatest Information Update: 25 Jun 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Intra-Cellular Therapies
- Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
- Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar depression; Schizophrenia
- Phase III Behavioural disorders; Bipolar disorders; Major depressive disorder
- Phase II Sleep maintenance insomnia
Most Recent Events
- 18 Jun 2024 Efficacy and safety data from the phase III trial in Major depressive disorder released by Intra-Cellular Therapies
- 17 Jun 2024 Intra-Cellular Therapies plans a phase III trial for Bipolar I disorders in USA (PO, Capsule) in July 2024 (NCT06462612)
- 01 Jun 2024 Intra-Cellular Therapies initiates enrolment in a phase III trial for Bipolar disorders in USA (NCT06462586)